T1	Organism 27 32	Human
T2	OrganismPart 33 38	Heart
T3	Disease 107 154	Dilated Left Atrium Without Atrial Fibrillation
T4	Disease 432 453	mitral valve prolapse
T5	Disease 455 458	MVP
*	Equiv T4 T5
T6	OrganismPart 713 724	right atria
T7	OrganismPart 726 728	RA
T8	OrganismPart 731 741	left atria
T9	OrganismPart 743 745	LA
T10	OrganismPart 767 769	LV
T11	OrganismPart 751 765	left ventricle
*	Equiv T6 T7
*	Equiv T8 T9
*	Equiv T11 T10
T12	Sex 780 784	male
T13	NumberOfBiologicalReplicates 774 779	seven
T14	Disease 831 862	dilated LA but no history of AF
T15	SupplementaryFile 5897 5920	Supplementary Materials
T16	NumberOfBiologicalReplicates 5990 5995	seven
T17	OrganismPart 6065 6067	LA
T18	OrganismPart 6069 6071	RA
T19	OrganismPart 6073 6075	LV
T20	NumberOfSamples 6087 6097	21 samples
T21	FractionationMethod 990 1025	high-pressure liquid chromatography
T22	Instrument 1055 1077	Q-Exactive-HF Orbitrap
T24	OrganismPart 7298 7300	LA
T25	OrganismPart 7302 7304	RA
T26	OrganismPart 7309 7311	LV
T27	ConcentrationOfCompound 7746 7751	50 mm
T23	NumberOfTechnicalReplicates 6196 6198	No
T28	Compound 7752 7760	Tris-HCl
T29	ConcentrationOfCompound 7761 7767	pH 8.5
T30	ConcentrationOfCompound 7769 7773	5 mm
T31	ConcentrationOfCompound 7780 7786	150 mm
T32	ConcentrationOfCompound 7793 7798	10 mm
T33	ConcentrationOfCompound 7804 7806	1%
T34	ConcentrationOfCompound 7821 7825	5 mm
T35	ConcentrationOfCompound 7831 7835	5 mm
T36	ConcentrationOfCompound 7859 7863	1 mm
T37	ConcentrationOfCompound 7893 7895	1x
T38	ConcentrationOfCompound 8238 8240	6M
T39	ConcentrationOfCompound 8249 8254	50 mm
T40	ConcentrationOfCompound 8264 8270	pH 8.5
T41	ConcentrationOfCompound 8272 8276	5 mm
T42	ConcentrationOfCompound 8282 8286	5 mm
T43	ConcentrationOfCompound 8310 8314	1 mm
T44	ConcentrationOfCompound 8344 8346	1x
T45	Compound 7774 7778	EDTA
T46	Compound 7787 7791	NaCl
T47	Compound 7799 7802	KCl
T48	Compound 7807 7819	Triton X-100
T49	Compound 7836 7857	beta-glycerophosphate
T50	Compound 7864 7880	Na-orthovanadate
T51	Compound 7911 7929	protease inhibitor
T52	Compound 8233 8236	HCl
T53	Compound 8244 8247	HCl
T54	Compound 8255 8263	Tris HCl
T55	Compound 8277 8280	NaF
T56	Compound 8287 8308	beta-glycerophosphate
T57	Compound 8315 8331	Na-orthovanadate
T58	Compound 8362 8380	protease inhibitor
T59	ReductionReagent 8466 8495	Tris(2-carboxyethyl)phosphine
T60	ReductionReagent 8497 8501	TCEP
*	Equiv T59 T60
T61	ConcentrationOfCompound 8461 8465	5 mm
T62	AlkylationReagent 8513 8528	chloroacetamide
T63	AlkylationReagent 8530 8533	CAA
*	Equiv T62 T63
T64	Time 8586 8592	15 min
T65	FactorValue 6065 6067	LA
T66	FactorValue 6069 6071	RA
T67	FactorValue 6073 6075	LV
T68	CleavageAgent 8668 8673	Lys-C
T69	CleavageAgent 8843 8850	trypsin
T70	Compound 8966 8986	trifluoroacetic acid
T71	FractionationMethod 9206 9270	micro-flow reverse-phase ultrahigh pressure liquid chromatograpy
T72	FractionationMethod 9272 9276	UPLC
*	Equiv T71 T72
T73	Chromatography 9284 9309	Dionex UltiMate 3000 UPLC
T74	FractionationFraction 8988 8995	Soluble
T75	Instrument 9694 9752	Q-Exactive HF quadrupole Orbitrap tandem mass spectrometer
T76	IonizationType 10479 10496	nano-electrospray
T77	FractionationMethod 10766 10771	Top12
T78	Label 11397 11407	label-free
T79	Label 11424 11427	LFQ
*	Equiv T78 T79
T80	Age 11782 11793	middle aged
T81	Age 11803 11811	50 years
T83	Disease 11856 11954	mitral valve regurgitation with dilated left atria and a normal left ventricular ejection fraction
T84	Disease 12094 12113	atrial fibrillation
T85	CleavageAgent 12766 12771	Lys-C
T86	CleavageAgent 12776 12783	trypsin
T82	SupplementaryFile 11993 12001	Table S1
